Table 3.
Comparison of clinical efficacy
| Group | CR | PR | SD | PD | ORR | DCR |
|---|---|---|---|---|---|---|
| TACE (n = 20) | 0 (0.00) | 5 (25.00) | 5 (25.00) | 10 (50.00) | 5 (25.00)* | 10 (50.00)* |
| TACE+AH (n = 34) | 0 (0.00) | 15 (44.12) | 7 (20.59) | 12 (35.29) | 15 (44.12)* | 22 (64.71) |
| TACE+IMRT (n = 18) | 2 (11.11) | 13 (72.22) | 1 (5.56) | 2 (11.11) | 15 (83.33) | 16 (88.89) |
| χ2 value | 6.068 | 6.559 | ||||
| P value | 0.194 | 0.038 |
Note: Compared with the TACE+IMRT group;
*
P < 0.05.
Abbreviations: TACE, transcatheter arterial chemoembolization; AH, anlotinib hydrochloride; IMRT, intensity-modulated radiotherapy. The disappearance of the target lesion was assessed as complete remission (CR). PR, partial remission; PD, progressive disease; SD, stable disease; ORR, objective response rate; DCR, disease control rate.